<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-108198</identifier>
<setSpec>1137-6627</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Dabigatran as a therapeutic possibility in heparin-induced thrombocytopenia type II</dc:title>
<dc:description xml:lang="en">The syndrome of heparin-induced thrombocytopenia(HIT), with an incidence of 0.2-0.5% in patients exposed to heparin for more than 4 days, is produced by an immune alteration with the formation of antibodies against the heparin platelet factor 4 complex. It presents a wide spectrum of clinical manifestations, the most frequent of which are thrombocytopenia, thrombotic arterial-venous phenomena, and cutaneous necrosis. Up to the present, lepiridin, recently suspended, and argatroban (direct thrombin inhibitors) have been the approved medicines normally used in treatment, administered in parenteral form. Dabigatran, a new anticoagulant medicine that is a direct and reversible thrombin inhibitor, could theoretically be a medicine employed in treating HIT. According to the bibliography consulted we are presenting the first case of HIT treated with dabigatran in the medical literature(AU)</dc:description>
<dc:creator>Alonso, J. L</dc:creator>
<dc:creator>Pérez Ricarte, S</dc:creator>
<dc:creator>Urbieta, M</dc:creator>
<dc:creator>Anniccherico, F. J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El síndrome de trombocitopenia inducido por heparina (HIT) con una incidencia del 0,2-0,5 % en pacientes expuestos a heparina durante más de 4 días, es producido por una alteración inmune con formación de anticuerpos frente al complejo heparina-factor 4plaquetario, que presenta un amplio espectro de manifestaciones clínicas: siendo la trombocitopenia, los fenómenos trombóticos arteriales/venosos y la necrosis cutánea los más frecuentes. Hasta el momento actual, lepirudina, recientemente suspendida y argatroban (inhibidores directos de la trombina) son los fármacos aprobados y habitualmente usados en el tratamiento, suministrados de forma parenteral. El dabigatran, un nuevo fármaco anticoagulante, inhibidor directo y reversible de la trombina teóricamente podría ser un fármaco empleado en el tratamiento del HIT. Según la bibliografía consultada presentamos el primer caso de HIT tratada con dabigatran en la literatura médica(AU)</dc:description>
<dc:source>An Sist Sanit Navar;35(3): 521-524, sept.-dic. 2012. graf</dc:source>
<dc:identifier>ibc-108198</dc:identifier>
<dc:title xml:lang="es">Dabigatran como posibilidad terapéutica en el síndrome de trombocitopenia inducida por heparina tipo II</dc:title>
<dc:subject>^d23279^s22020</dc:subject>
<dc:subject>^d14306^s22057</dc:subject>
<dc:subject>^d14306^s22036</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d932^s22078</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:type>article</dc:type>
<dc:date>201212</dc:date>
</metadata>
</record>
</ibecs-document>
